Mark Leick News Today

Mark Leick, MD, discusses the challenges and limitations associated with the use of CAR T-cell therapy across hematologic malignancies, highlighting how ongoing research may potentially ameliorate present unmet needs.

Mark Leick, MD, discusses the varying role of CAR T-cell therapy across various hematologic malignancies, elaborating on the cause of its effectiveness in these disease spaces.

Mark Leick, MD, discusses how the emergence of CAR T-cell therapies have affected the treatment paradigms in various hematologic malignancies, expands on how persisting challenges with the use of this type of treatment are being addressed, and details research into the use of CAR T-cell therapy in patients with solid tumors.

Five seriously ill lupus patients have seen their disease driven into remission after a single infusion of modified immune cells, in a small trial that borrows from cancer therapy to harness patients' own cells to treat the autoimmune condition.

CAR-T immune therapies were developed to fight cancer. The same technique just showed promise treating lupus, but it costs hundreds of thousands.